1. [CASE 1 — QUESTION 1] At the four-week follow-up visit, her resting ECG shows a QRS duration of 102 ms compared with 86 ms at baseline (before flecainide). Her resting heart rate is 58 beats per minute and she has been asymptomatic with no AF recurrences. Which of the following best interprets this ECG finding and guides the correct management decision?

• A) The QRS increase from 86 ms to 102 ms represents an 18.6 percent increase above baseline; this exceeds the acceptable threshold of 15 percent and mandates immediate flecainide discontinuation and emergency cardiology consultation
• B) The QRS increase is irrelevant because resting ECG QRS duration is not a valid monitoring parameter for Class Ic agents; toxicity from flecainide manifests exclusively through symptomatic arrhythmia and not through asymptomatic ECG changes; no dose adjustment is needed
• C) The QRS increase from 86 ms to 102 ms represents an 18.6 percent increase above baseline, which is below the widely used 25 percent threshold for sodium channel toxicity; in a patient who is asymptomatic with excellent rhythm control and no structural heart disease, this finding is reassuring but warrants continued monitoring ; ideally including an exercise ECG to assess rate-dependent QRS widening at faster heart rates, where use-dependent sodium channel block is more pronounced
• D) The QRS increase reflects the expected pharmacodynamic effect of metoprolol rather than flecainide; beta-blockade slows heart rate and prolongs the QRS by reducing phase 0 upstroke velocity; flecainide dose adjustment is not required and the metoprolol dose should be reduced to restore normal QRS duration
• E) The QRS duration of 102 ms with a resting heart rate of 58 beats per minute indicates excessive use-dependent sodium channel block from the combination of flecainide's Class Ic effect and metoprolol's rate-reducing effect; the combination of these two drugs produces pharmacodynamic synergy on the His-Purkinje system requiring dose reduction of both agents

2. [CASE 1 — QUESTION 2] An exercise treadmill test is performed. At a heart rate of 112 beats per minute during the Bruce protocol, her QRS duration is 138 ms. Her blood pressure response is appropriate and she experiences no symptoms or arrhythmia during or after the test. Which of the following best interprets this exercise ECG finding?

• A) The QRS duration of 138 ms at a heart rate of 112 beats per minute represents a 60.5 percent increase above the pre-treatment baseline of 86 ms; this substantially exceeds the 25 percent warning threshold for sodium channel toxicity; even in the absence of symptoms or arrhythmia, this degree of rate-dependent QRS widening indicates excessive use-dependent sodium channel block and warrants flecainide dose reduction ; typically to 50 mg twice daily ; with repeat exercise ECG assessment after dose adjustment
• B) The QRS duration of 138 ms at exercise is acceptable because the 25 percent threshold applies to the resting QRS on flecainide (102 ms), not to the pre-treatment baseline; the exercise QRS represents a 35.3 percent increase above the resting-on-drug QRS of 102 ms, but exercise-related QRS widening beyond 50 percent of the on-drug resting value is the correct threshold; this patient has not crossed that threshold
• C) The exercise QRS widening is expected and benign; all patients on flecainide show rate-dependent QRS widening during exercise and the absolute QRS duration of 138 ms is within the range accepted for patients in sinus rhythm without bundle branch block; dose reduction is not required in an asymptomatic patient with normal hemodynamic response
• D) The finding confirms that flecainide is working correctly; progressive QRS widening with increasing heart rate demonstrates appropriate use-dependent sodium channel block that would be antiarrhythmic during any recurrence of AF at similar rates; the degree of widening is evidence of therapeutic efficacy, not toxicity
• E) Flecainide should be discontinued immediately and the patient hospitalized for cardiac monitoring; exercise-induced QRS widening above 130 ms in any patient on a Class Ic agent represents an imminent risk of exercise-triggered ventricular fibrillation requiring urgent electrophysiology consultation

3. [CASE 1 — QUESTION 3] The flecainide dose is reduced to 50 mg twice daily. Three weeks later she presents to the emergency department with palpitations and presyncope. Her ECG shows a regular tachycardia at 240 beats per minute with wide QRS complexes (136 ms) and visible organized atrial flutter waves. Blood pressure is 94/60 mmHg. She is on metoprolol 25 mg twice daily. Which of the following best explains this arrhythmia and guides immediate management?

• A) This represents ventricular tachycardia from flecainide proarrhythmia in structurally normal myocardium; the flutter-like appearance is atrial activity coincidentally visible during VT; immediate intravenous amiodarone is the treatment of choice for flecainide-associated VT in structurally normal hearts
• B) This represents atrial flutter with 2:1 AV conduction being misread as 1:1; the ventricular rate of 240 beats per minute at 2:1 flutter would require an atrial rate of 480 beats per minute, which is physiologically impossible; adenosine 6 mg IV should be given to slow the rate and clarify the diagnosis
• C) This represents AF with rate-dependent aberrant conduction through the right bundle branch; flecainide's dose reduction has allowed AF to recur at rates that produce left bundle branch-like aberrancy; intravenous metoprolol will slow the rate and narrow the QRS by improving AV nodal filtering
• D) This is expected and acceptable flutter at 240 beats per minute with 1:1 conduction; flecainide at the reduced dose is only partially slowing the flutter rate; increasing the flecainide dose back to 100 mg twice daily will slow the flutter rate further to below 150 beats per minute where the AV node can maintain 2:1 block
• E) This is atrial flutter with 1:1 AV conduction ; flecainide's sodium channel block in atrial tissue has slowed the AF to organized flutter at 240 beats per minute, and the metoprolol dose of 25 mg twice daily has provided insufficient AV nodal protection to prevent 1:1 conduction at this rate; the patient is hemodynamically compromised (BP 94/60 mmHg) and immediate synchronized DC cardioversion is the correct management, followed by a reassessment of the entire rhythm control strategy

4. [CASE 1 — QUESTION 4] After successful cardioversion to sinus rhythm, flecainide is discontinued. The patient remains symptomatic from paroxysmal AF and desires rhythm control. She has no asthma, no structural heart disease, and no renal impairment. Her cardiologist considers alternative rhythm control options. Which of the following correctly identifies a safe and appropriate next step for rhythm control in this patient?

• A) Restart flecainide at a lower dose of 50 mg once daily with the metoprolol increased to 100 mg twice daily; the prior complication reflected inadequate AV nodal protection rather than a flecainide-specific problem, and lower-dose flecainide with more robust rate-limiting will prevent recurrence of flutter 1:1
• B) Dronedarone is a reasonable alternative rhythm control option in this patient with no structural heart disease, no HFrEF, and no permanent AF; it provides multi-class antiarrhythmic activity without the Class Ic proarrhythmic profile that produced the flutter complication, and can be prescribed with standard monitoring for hepatic and pulmonary effects; propafenone is also an option given the absence of asthma, but carries the same flutter 1:1 risk as flecainide if prescribed without adequate AV nodal protection
• C) Amiodarone is the only appropriate rhythm control option; after a Class Ic proarrhythmic event, all other rhythm control agents are contraindicated because the flutter 1:1 mechanism demonstrates that this patient's AV node cannot adequately filter rapid supraventricular rates regardless of which drug is prescribed
• D) Sotalol 80 mg twice daily is the most appropriate next agent; it provides rhythm control through IKr blockade without the sodium channel-mediated flutter rate-slowing that allowed 1:1 conduction; because the patient has normal renal function, no dose adjustment is needed and outpatient initiation is safe
• E) Catheter ablation of the atrial flutter circuit is the only appropriate management; pharmacological rhythm control is permanently contraindicated after documented flutter 1:1 on any Class Ic agent, and all future rhythm control must be non-pharmacological

5. [CASE 2 — QUESTION 1] Which of the following represents the most appropriate immediate pharmacological approach for termination of this hemodynamically stable sustained VT in this patient with structural heart disease?

• A) Intravenous flecainide 2 mg/kg over 10 minutes; flecainide is the most potent sodium channel blocker and provides the most reliable pharmacological VT termination; its Class Ic mechanism is specifically effective for monomorphic re-entrant VT circuits in ischemic myocardium
• B) Intravenous lidocaine 1.5 mg/kg bolus followed by infusion at 2 to 3 mg/min; lidocaine Class Ib preferential activity in ischemic and depolarized tissue makes it a reasonable option, though amiodarone is now preferred at most centers for hemodynamically stable VT in structural heart disease
• C) Intravenous quinidine gluconate 10 mg/kg over 60 minutes; Class Ia agents are not subject to the CAST contraindication and quinidine has established efficacy for VT termination in ischemic cardiomyopathy through combined sodium and potassium channel blockade
• D) Intravenous amiodarone 150 mg over 10 minutes followed by 1 mg/min infusion; amiodarone is preferred for pharmacological termination of hemodynamically stable VT in structural heart disease because it provides multi-class antiarrhythmic activity, does not carry the CAST contraindication, is not negatively inotropic in the short term at standard IV doses, and has established efficacy in this clinical scenario
• E) Synchronized DC cardioversion at 100 joules; pharmacological management is contraindicated in all patients with sustained VT and structural heart disease because any antiarrhythmic drug in this context carries unacceptable proarrhythmic risk; electrical cardioversion is the only safe first-line intervention

6. [CASE 2 — QUESTION 2] After successful VT termination with amiodarone, a lidocaine infusion is started at 2 mg/min for additional VT suppression. Forty-five minutes later the patient reports ringing in his ears and slurred speech. His blood pressure is 118/72 mmHg, heart rate is 76 beats per minute, and the QRS on the monitor is 88 ms ; identical to his pre-VT sinus rhythm baseline. Which of the following is the correct immediate action?

• A) Increase the lidocaine infusion to 3 mg/min; tinnitus and slurred speech during lidocaine infusion represent a paradoxical subtherapeutic excitatory reaction seen at low plasma concentrations, and achieving therapeutic levels will suppress these CNS symptoms
• B) Add intravenous diazepam 5 mg immediately as seizure prophylaxis before reducing the lidocaine dose; tinnitus and slurred speech reliably predict seizures within 5 minutes, and benzodiazepine prophylaxis must precede any dose manipulation
• C) Reduce or stop the lidocaine infusion immediately; tinnitus and slurred speech are early CNS toxicity signs appearing at plasma concentrations of approximately 3 to 6 mcg/mL, representing the warning window before cardiac toxicity which occurs at approximately 8 to 12 mcg/mL; the unchanged QRS confirms cardiac sodium channels are not yet significantly blocked; dose reduction now prevents progression to seizures
• D) Continue the infusion and recheck the QRS duration in 15 minutes; tinnitus and slurred speech are common vestibular and cerebellar adverse effects of therapeutic lidocaine infusions that resolve spontaneously at steady-state concentrations without dose adjustment
• E) Stop the lidocaine infusion and start intravenous mexiletine at a loading dose of 250 mg over 30 minutes; mexiletine is the Class Ib alternative to lidocaine and switching agents will provide continued VT suppression while eliminating the lidocaine CNS toxicity

7. [CASE 2 — QUESTION 3] The lidocaine infusion is stopped and the team considers intravenous procainamide as an alternative agent for VT suppression. The patient's CrCl is 44 mL/min from pre-existing CKD. Which of the following best describes the specific risk and monitoring requirement if procainamide is used in this patient?

• A) N-acetylprocainamide (NAPA), the principal metabolite of procainamide formed by hepatic N-acetyltransferase 2 (NAT2), is eliminated almost entirely by renal excretion; in a patient with CrCl of 44 mL/min, NAPA clearance is substantially reduced and NAPA will accumulate, producing progressive QTc prolongation from its IKr-blocking Class III activity even when procainamide plasma levels remain within the therapeutic range; NAPA plasma levels must be measured alongside procainamide levels, the QTc monitored continuously, and the infusion duration limited to the minimum required; procainamide should be considered high-risk in this patient and alternative VT management strongly preferred
• B) Procainamide is safe at standard doses in a CrCl of 44 mL/min because the drug itself is predominantly metabolized by the liver; the CrCl threshold requiring dose reduction for procainamide is below 20 mL/min, at which point renal accumulation of the parent drug becomes clinically significant; above this threshold, no modification is required
• C) The primary concern with procainamide in CrCl 44 mL/min is accumulation of the parent drug rather than NAPA; procainamide's sodium channel blocking activity at elevated plasma concentrations causes progressive QRS widening that can precipitate His-Purkinje block; monitoring the QRS duration every 15 minutes is sufficient to detect and respond to this toxicity before cardiac arrest
• D) Procainamide is contraindicated in this patient because his structural heart disease (prior MI, LVEF 32%) invokes the CAST principle, which applies to all Class I antiarrhythmic agents including Class Ia procainamide when used in the post-MI setting; amiodarone is the only Class I-independent option
• E) Procainamide should be avoided in this patient primarily because of the risk of drug-induced lupus-like syndrome (DILS) developing rapidly in patients with pre-existing renal impairment; reduced renal clearance accelerates hydroxylamine metabolite accumulation and produces DILS within 24 to 48 hours of IV administration in patients with CrCl below 50 mL/min

8. [CASE 2 — QUESTION 4] The patient's VT is successfully suppressed and he is stabilized. His electrophysiology team discusses long-term management of his VT risk with LVEF 32% and prior MI. Which of the following best represents the appropriate long-term antiarrhythmic management plan for this patient?

• A) Oral flecainide 100 mg twice daily with metoprolol for rhythm control; Class Ic agents are appropriate for long-term VT suppression in patients with structural heart disease when the LVEF remains above 30%, the VT is monomorphic (indicating a fixed re-entrant substrate), and a beta-blocker is co-prescribed for AV nodal protection
• B) Oral mexiletine 200 mg three times daily as monotherapy; mexiletine's Class Ib preferential activity in ischemic tissue makes it the single most effective agent for chronic VT suppression in ischemic cardiomyopathy, and it can be used as sole antiarrhythmic therapy without implantable cardioverter-defibrillator (ICD) consideration in patients with stable LVEF above 30%
• C) Oral amiodarone 200 mg daily alone without ICD; amiodarone reduces VT episodes and arrhythmic death in ischemic cardiomyopathy and is the preferred single-drug strategy in patients who cannot tolerate ICD implantation from allergic reactions to device materials
• D) Oral sotalol 80 mg twice daily; sotalol's combined beta-blocking and Class III IKr-blocking activity provides effective VT suppression in ischemic cardiomyopathy and has demonstrated superiority over amiodarone for monomorphic VT prevention in the SWORD (Survival With Oral d-sotalol) trial; no ICD is required if VT is monomorphic at presentation
• E) Implantable cardioverter-defibrillator (ICD) implantation is the cornerstone of management in a patient with ischemic cardiomyopathy, LVEF 32%, and sustained VT ; this meets both secondary prevention ICD criteria (documented sustained VT with structural disease) and would meet primary prevention criteria based on LVEF alone; antiarrhythmic therapy with amiodarone and consideration of adjunctive mexiletine may reduce VT burden and ICD shock frequency; Class Ic agents are absolutely contraindicated and must never be prescribed in this patient

9. [CASE 3 — QUESTION 1] Based on the clinical presentation, QTc of 524 ms, T-wave morphology, and genetic result showing a pathogenic KCNH2 loss-of-function variant, which of the following correctly identifies the congenital long QT syndrome subtype and explains the electrophysiological basis for QT prolongation in this patient?

• A) This is long QT syndrome type 1 (LQT1), caused by loss-of-function mutations in KCNQ1 encoding the slow delayed rectifier potassium channel (IKs); the characteristic T-wave morphology is a broad-based T-wave, and arrhythmic events are typically triggered by exercise or sympathetic activation; treatment is beta-blocker therapy, which is highly effective in LQT1
• B) This is long QT syndrome type 2 (LQT2), caused by loss-of-function mutations in KCNH2 (also known as hERG) encoding the rapid delayed rectifier potassium channel (IKr); reduced IKr current impairs ventricular repolarization and prolongs action potential duration and QTc; the characteristic T-wave morphology is bifid (notched), as seen in this patient, and arrhythmic events are often triggered by auditory stimuli or emotional arousal; beta-blocker therapy is the cornerstone of management
• C) This is long QT syndrome type 3 (LQT3), caused by loss-of-function mutations in SCN5A encoding the cardiac fast sodium channel (Nav1.5); gain-of-function mutations generate a persistent late inward sodium current (INa,late) that prolongs the action potential plateau; arrhythmic events classically occur at rest or during sleep; mexiletine specifically targets INa,late and is a mechanistically appropriate adjunct in LQT3
• D) This is long QT syndrome type 2 (LQT2), but the genetic variant identified is a gain-of-function mutation in KCNH2 that produces excessive IKr current, paradoxically prolonging repolarization through channel runaway kinetics that prevent timely channel closure during repolarization; this gain-of-function mechanism explains why standard potassium channel blockers worsen QT in this subtype
• E) This is long QT syndrome type 1 (LQT1), because KCNH2 encodes a structural protein of the IKs channel complex rather than the IKr channel; the loss-of-function in this structural protein indirectly reduces IKs activity, producing the LQT1 phenotype despite a KCNH2 genetic variant; the IKs deficiency is treated with beta-blockers and potassium supplementation

10. [CASE 3 — QUESTION 2] The patient is started on nadolol 40 mg daily. Her cardiologist discusses the importance of avoiding QT-prolonging medications. Her general practitioner subsequently prescribes azithromycin for a respiratory tract infection. Which of the following best explains the risk of this prescription in this patient?

• A) Azithromycin is safe in LQT2 patients on beta-blockers because the combined rate-slowing effect of nadolol and azithromycin's vagotonic properties reduces the risk of pause-dependent torsades de pointes by preventing the bradycardia-related QTc prolongation that would otherwise trigger arrhythmia
• B) Azithromycin is safe in LQT2 because macrolide antibiotics affect only IKs channels (encoded by KCNQ1), and this patient's channel defect involves IKr (KCNH2); drugs that impair IKs are safe in a patient whose repolarization is already impaired at the IKr level because they affect a distinct repolarization pathway
• C) Azithromycin is safe in LQT2 patients who have a QTc below 550 ms at baseline; this patient's QTc of 524 ms is below this threshold, and short-course macrolide therapy for an acute infection does not produce clinically significant additional QTc prolongation
• D) Azithromycin blocks IKr potassium channels ; the same channel already reduced by the loss-of-function KCNH2 mutation in this patient; by further reducing the already-deficient IKr current, azithromycin adds to the repolarization impairment, potentially prolonging the QTc to levels at which torsades de pointes risk is substantially increased; macrolide antibiotics and all other IKr-blocking drugs are specifically contraindicated in LQT2, and an alternative antibiotic (such as amoxicillin) must be prescribed
• E) The risk of azithromycin in LQT2 is primarily pharmacokinetic rather than pharmacodynamic; azithromycin inhibits CYP3A4 (cytochrome P450 3A4), reducing the metabolism of nadolol and raising nadolol plasma concentrations to toxic levels that produce excessive AV nodal block and a long pause, creating the pause-dependent trigger for torsades de pointes

11. [CASE 3 — QUESTION 3] The azithromycin is discontinued and replaced with amoxicillin. Three months later, on nadolol therapy, the patient experiences a syncopal episode triggered by her phone alarm. Her QTc on a subsequent ECG is 538 ms. A colleague suggests adding mexiletine. Which of the following best explains whether mexiletine is appropriate for this patient?

• A) Mexiletine is appropriate because it blocks sodium channels during phase 0, shortening the action potential duration throughout the ventricle and thereby reducing the QTc through a non-subtype-specific mechanism that benefits all long QT subtypes regardless of the underlying genetic defect
• B) Mexiletine is appropriate because her breakthrough syncope on beta-blocker therapy indicates that the nadolol dose is inadequate; mexiletine's Class Ib properties will potentiate the antiarrhythmic effect of nadolol through pharmacodynamic synergy at the AV node, reducing the risk of pause-dependent TdP
• C) Mexiletine is not appropriate for this patient with LQT2; mexiletine's mechanistic benefit is specifically in LQT3, where gain-of-function SCN5A mutations produce a pathological persistent late sodium current (INa,late) that mexiletine blocks; in LQT2, the QT prolongation arises from IKr deficiency due to the KCNH2 loss-of-function mutation, not from excess sodium current; mexiletine has no mechanism to correct IKr deficiency and will not shorten the QTc in this patient; ICD implantation should be strongly considered given breakthrough syncope on beta-blocker therapy
• D) Mexiletine is appropriate as an empirical antiarrhythmic because all patients with congenital long QT syndrome (LQTS) and QTc above 530 ms should receive mexiletine regardless of the specific LQT subtype; the drug's general sodium channel-stabilizing properties provide non-specific antiarrhythmic protection that reduces TdP risk across all LQTS subtypes
• E) Mexiletine is contraindicated in all long QT syndrome patients because sodium channel blockade reduces the phase 0 upstroke velocity and impairs the rapid depolarization that is necessary to terminate re-entrant circuits underlying TdP; mexiletine would worsen TdP frequency in any LQTS patient

12. [CASE 3 — QUESTION 4] The cardiologist decides against mexiletine and recommends ICD implantation. The patient asks whether she can discontinue nadolol after the ICD is implanted, since the device will protect her from sudden death. Which of the following best explains the ongoing role of beta-blocker therapy after ICD implantation in this patient?

• A) Beta-blocker therapy should be continued lifelong after ICD implantation; the ICD treats cardiac arrest when TdP degenerates to ventricular fibrillation but does not prevent TdP from occurring; nadolol reduces the frequency of TdP episodes by reducing sympathetic triggers that initiate arrhythmia in LQT2, thereby reducing the burden of ICD shocks, which are painful and associated with reduced quality of life and psychological distress; the ICD and beta-blocker are complementary ; the beta-blocker reduces arrhythmia burden and the ICD provides a safety net for breakthrough events
• B) Beta-blocker therapy can be discontinued six months after ICD implantation once the device is confirmed to be functioning correctly on remote monitoring; after that point, the ICD provides complete arrhythmia protection and the pharmacological therapy adds only adverse effects without additional benefit
• C) Beta-blocker therapy should be changed from nadolol to metoprolol after ICD implantation because metoprolol is more selective for beta-1 receptors and does not impair the ICD's ability to detect ventricular arrhythmias through its effect on AV conduction; nadolol's non-selective beta-2 blockade interferes with the ICD's ventricular sensing algorithms
• D) Beta-blocker therapy should be discontinued immediately; nadolol's rate-slowing properties increase the diastolic interval and amplify pause-dependent QTc prolongation, which is the primary trigger for TdP in LQT2; now that the ICD is present, the rate-protective effect of beta-blockade is unnecessary and its QTc-amplifying effect is the dominant risk
• E) The decision to continue or discontinue beta-blocker therapy after ICD implantation should be based on QTc response; if the QTc normalizes below 470 ms on nadolol after ICD implantation, the drug can be tapered and stopped; if the QTc remains above 470 ms, nadolol should be continued indefinitely

13. [CASE 4 — QUESTION 1] Which of the following most appropriately describes the pharmacological rationale for selecting disopyramide combined with an AV nodal blocking agent as rhythm control therapy in this patient?

• A) Disopyramide is selected for its Class Ia IKr-blocking properties that prolong the effective refractory period throughout the atrial myocardium, converting persistent AF to sinus rhythm through pharmacological cardioversion; the AV nodal blocking agent is added to prevent excessive ventricular rate acceleration from disopyramide's sodium channel block in atrial tissue
• B) Disopyramide is selected because among all Class I agents it produces the least QRS widening, making it safest in a patient with marked LV hypertrophy (wall thickness 22 mm) where additional conduction slowing would create re-entrant substrates in the hypertrophied septum
• C) Disopyramide is selected because its potent IKr blockade provides Class III antiarrhythmic activity that is superior to amiodarone for rhythm control in HOCM, with less pulmonary and thyroid toxicity; the AV nodal blocker prevents 1:1 flutter conduction from the Class III mechanism
• D) Disopyramide is selected because its alpha-adrenergic blocking properties reduce systemic vascular resistance and ventricular afterload, which directly decreases the LVOT gradient in HOCM through afterload reduction; the AV nodal blocker provides rate control during the transition to the new hemodynamic state
• E) Disopyramide is selected specifically because of its pronounced negative inotropic effect, which directly reduces left ventricular contractility and thereby decreases the dynamic LVOT gradient in this patient with obstructive HOCM ; a guideline-recognized niche indication; an AV nodal blocking agent is mandatory because disopyramide's antimuscarinic properties block vagal tone at the AV node, which would accelerate ventricular rate in AF without AV nodal protection; in this patient with CrCl of 40 mL/min, the AV nodal blocker of choice is diltiazem or verapamil rather than a beta-blocker, to avoid the pharmacokinetic interaction that would accumulate if a cytochrome P450 2D6 (CYP2D6)-metabolized beta-blocker were combined with propafenone; disopyramide itself will require renal dose adjustment given its significant renal elimination

14. [CASE 4 — QUESTION 2] Disopyramide 100 mg three times daily combined with diltiazem is started. After three weeks, the patient's LVOT gradient has fallen from 72 mmHg to 28 mmHg and the ventricular rate is well-controlled at 68 to 80 beats per minute. However, his QTc has increased from 428 ms at baseline to 512 ms. He has no symptoms attributable to the QTc prolongation. Which of the following best explains the QTc change and guides management?

• A) The QTc of 512 ms is an expected and acceptable pharmacodynamic response to disopyramide's IKr-blocking activity in HOCM patients; QTc values up to 560 ms are acceptable in HOCM because the hypertrophied myocardium has increased repolarization reserve that blunts the TdP risk associated with QT prolongation in normal myocardium; no dose adjustment is required
• B) Disopyramide prolongs the QTc through IKr blockade (a Class Ia property shared by all Class Ia agents); in this patient with CrCl of 40 mL/min, accumulation of both disopyramide and its active metabolite at reduced renal clearance may be contributing to greater-than-expected QTc prolongation; a QTc of 512 ms exceeds the widely used 500 ms threshold for TdP risk and warrants dose reduction, reassessment of disopyramide levels if available, and close clinical monitoring; the therapeutic benefit (LVOT gradient reduction) must be weighed against the growing proarrhythmic risk of further QTc prolongation
• C) The QTc prolongation is caused by diltiazem rather than disopyramide; non-dihydropyridine calcium channel blockers are potent IKr blockers that produce clinically significant QTc prolongation in patients with HOCM, where hypertrophied myocardium has altered repolarization kinetics; switching from diltiazem to verapamil, which has less IKr-blocking activity, will normalize the QTc
• D) The QTc of 512 ms is caused by hypokalemia from diltiazem-induced renal potassium wasting; non-dihydropyridine calcium channel blockers activate aldosterone secretion through calcium-dependent pathways in the adrenal cortex, producing secondary hyperaldosteronism and potassium depletion; serum potassium should be checked and corrected before any antiarrhythmic dose adjustment
• E) The QTc prolongation is an artifact of the LVOT gradient reduction; as the LVOT gradient decreases, the T-wave morphology in the mid-precordial leads normalizes, producing an apparent prolongation of QTc measurement that does not reflect true repolarization abnormality; no pharmacological intervention is required

15. [CASE 4 — QUESTION 3] The disopyramide dose is reduced to 100 mg twice daily. QTc stabilizes at 488 ms and the LVOT gradient remains at 34 mmHg. However, the patient reports increasing urinary hesitancy, dry mouth, and constipation. Which of the following best explains these symptoms and guides management?

• A) These anticholinergic symptoms are caused by diltiazem's calcium channel blocking effect on smooth muscle throughout the body, producing decreased secretory gland activity and impaired smooth muscle relaxation in the bladder and bowel; switching from diltiazem to a beta-blocker will eliminate these symptoms while maintaining AV nodal protection
• B) The urinary hesitancy, dry mouth, and constipation represent a hypersensitivity reaction to disopyramide's sulfonamide-like chemical structure; these symptoms require immediate drug discontinuation and investigation for drug-induced lupus-like syndrome with ANA measurement
• C) These symptoms are expected adverse effects of diltiazem-induced constipation (a recognized side effect of non-dihydropyridine calcium channel blockers on colonic smooth muscle) and should be managed with dietary fiber and stool softeners without changing the antiarrhythmic regimen
• D) These are anticholinergic adverse effects of disopyramide's pronounced muscarinic receptor blocking properties, which affect smooth muscle and secretory glands throughout the body; the bladder smooth muscle relaxation impairs detrusor contraction, producing urinary hesitancy (particularly in men with prostatic hypertrophy); dry mouth reflects reduced salivary gland secretion; constipation reflects reduced intestinal motility; in this patient with CrCl of 40 mL/min, drug accumulation amplifies these anticholinergic effects; management options include further dose reduction if the LVOT gradient remains controlled, cholinergic agents (bethanechol) for urinary symptoms if severe, or drug discontinuation if intolerable
• E) These anticholinergic symptoms reflect paradoxical cholinomimetic toxicity from excessive AV nodal vagal enhancement; disopyramide at the current dose has saturated its antimuscarinic binding, producing a rebound cholinergic state that stimulates salivary glands excessively (wet mouth rather than dry mouth ; the question contains a clinical error); the drug should be continued at the current dose

16. [CASE 4 — QUESTION 4] The anticholinergic symptoms become intolerable and disopyramide is discontinued. The LVOT gradient returns to 64 mmHg. The cardiologist now needs to address both the LVOT obstruction and the AF. Which of the following best describes the appropriate next management step?

• A) Restart propafenone 150 mg three times daily with diltiazem; propafenone is a Class Ic agent with additional beta-blocking properties that will provide rate control and rhythm control; while Class Ic agents are generally avoided in structural disease, HOCM with preserved LVEF is specifically exempted from the CAST contraindication because the substrate is concentric hypertrophy rather than ischemic scar
• B) Restart flecainide 100 mg twice daily; the CAST contraindication does not apply to HOCM because HOCM myocardium has uniform hypertrophic remodeling without the heterogeneous ischemic fibrosis that creates the re-entrant substrate responsible for Class Ic proarrhythmia
• C) For the LVOT obstruction, consider referral for septal reduction therapy (surgical myectomy or alcohol septal ablation) and evaluate for mavacamten (a cardiac myosin inhibitor approved for symptomatic obstructive HOCM); for the AF rhythm control, amiodarone is the appropriate pharmacological agent given the structural heart disease ; it provides rhythm control without the Class Ic contraindication, though its long-term toxicity monitoring requirements must be addressed
• D) Restart quinidine 200 mg three times daily; quinidine's combined sodium and potassium channel blocking properties reduce the LVOT gradient through QT prolongation-mediated extension of ventricular diastole, which reduces the hypercontractile systolic state responsible for the obstructive gradient in HOCM
• E) Restart disopyramide at a lower dose of 50 mg twice daily with bethanechol to counteract the anticholinergic side effects; bethanechol's cholinergic stimulation will specifically reverse the urinary, salivary, and intestinal effects without affecting the cardiac antimuscarinic properties that are pharmacologically distinct from peripheral M3 receptor effects

17. [CASE 5 — QUESTION 1] Two weeks after starting quinidine, the patient presents with gum bleeding and blurred/yellowed visual disturbance. His INR is 4.1 and his serum digoxin level is 2.4 ng/mL. His ECG shows a junctional rhythm at 48 beats per minute with frequent ectopic beats. Which of the following best explains both drug interactions that have occurred simultaneously?

• A) Quinidine has produced two simultaneous pharmacokinetic drug interactions: (1) inhibition of CYP2C9 (cytochrome P450 2C9), the primary enzyme metabolizing S-warfarin, has raised warfarin plasma concentrations and prolonged the INR from 2.3 to 4.1, producing the clinical bleeding; and (2) inhibition of P-glycoprotein (P-gp) transport in the renal tubule and biliary epithelium has reduced digoxin elimination and raised the serum digoxin concentration from 0.8 to 2.4 ng/mL, producing the characteristic features of digoxin toxicity (junctional bradycardia, visual disturbances, frequent ectopy); both interactions were predictable and both doses required proactive adjustment when quinidine was initiated
• B) Both interactions are pharmacodynamic rather than pharmacokinetic; quinidine's IKr blockade produces additive anticoagulant effect by inhibiting vitamin K-dependent clotting factor synthesis in the liver, raising the INR; simultaneously, quinidine's AV nodal-enhancing antimuscarinic properties have shifted the ventricular pacemaker to junctional origin while the digoxin level remains therapeutic
• C) The INR elevation reflects quinidine inducing hepatic microsomal enzymes and paradoxically increasing the production of vitamin K epoxide reductase, which becomes overwhelmed and produces a rebound anticoagulation effect; the digoxin level elevation reflects impaired renal tubular secretion from quinidine's direct nephrotoxicity in the proximal tubule
• D) Both abnormalities reflect a single mechanism ; quinidine's significant protein binding displaces both warfarin and digoxin from albumin simultaneously, raising the free fractions of both drugs; the free warfarin elevation prolongs the INR and the free digoxin elevation produces toxicity; reducing quinidine plasma concentrations will restore protein binding equilibrium for both drugs
• E) The INR elevation is caused by quinidine inhibiting CYP3A4 (cytochrome P450 3A4), the primary warfarin-metabolizing enzyme, while the digoxin toxicity is caused by quinidine's direct sodium channel blockade in renal tubular cells impairing the active secretion of digoxin; both mechanisms are pharmacokinetic but through different pathways

18. [CASE 5 — QUESTION 2] The digoxin toxicity is confirmed. The patient is admitted. His heart rate is 42 beats per minute with a junctional rhythm, blood pressure is 94/60 mmHg, and potassium is 3.2 mEq/L. Which of the following correctly describes the appropriate immediate management of his digoxin toxicity?

• A) Administer intravenous calcium gluconate 10 mL of 10% solution immediately; calcium directly reverses digoxin's inhibition of the Na+/K+-ATPase by competing for the cation binding site, and is the specific antidote for digoxin-induced bradycardia and AV block
• B) Administer intravenous atropine 0.5 mg and restart the digoxin at a reduced dose of 0.0625 mg daily once the heart rate improves; atropine reverses the excessive vagal AV nodal slowing from digoxin toxicity, and the reduced digoxin dose with the lower quinidine concentration after drug-drug equilibration will produce an acceptable steady state
• C) Administer intravenous amiodarone 150 mg over 10 minutes to suppress the frequent ectopic beats; quinidine must be stopped but digoxin can be continued at the same dose because digoxin levels will normalize spontaneously once quinidine is stopped and P-glycoprotein inhibition is relieved
• D) Administer intravenous lidocaine 1.5 mg/kg bolus for the ventricular ectopy; stop both quinidine and digoxin; lidocaine is the agent of choice for digoxin-toxic ventricular arrhythmias because its Class Ib fast-recovery kinetics avoid the sodium channel-mediated potassium efflux that worsens digoxin toxicity
• E) Stop both quinidine and digoxin immediately; administer intravenous digoxin-specific antibody fragments (Fab, Digibind/DigiFab) for this hemodynamically significant digoxin toxicity (heart rate 42 beats per minute, blood pressure 94/60 mmHg, junctional rhythm, ventricular ectopy); correct the hypokalemia with intravenous potassium as low potassium amplifies digoxin toxicity by increasing Na+/K+-ATPase sensitivity to digoxin; continuous cardiac monitoring with temporary pacing available

19. [CASE 5 — QUESTION 3] The digoxin toxicity is successfully treated with Fab fragments. Both quinidine and digoxin are stopped. Forty-eight hours later, during hospital monitoring, the patient has a 12-second syncopal episode. The telemetry shows a 1.8-second sinus pause followed by a 12-second run of polymorphic ventricular tachycardia with a twisting morphology, after which sinus rhythm resumes. His QTc is 526 ms. Which of the following best explains this event?

• A) The polymorphic VT represents residual digoxin toxicity causing delayed afterdepolarization-triggered activity; despite Fab fragment treatment, tissue-bound digoxin releases slowly from Na+/K+-ATPase binding sites and continues to produce triggered activity for 48 to 96 hours after apparent clinical resolution
• B) This represents quinidine-induced torsades de pointes from residual IKr blockade; quinidine has a half-life of approximately 6 to 8 hours and, 48 hours after cessation, plasma levels may still be sufficient to produce clinically significant IKr blockade in this patient; the mechanism is the pause-dependent QTc prolongation from quinidine's reverse use-dependent IKr block ; the 1.8-second sinus pause maximally prolonged the QTc, triggering early afterdepolarizations and TdP; quinidine syncope occurring 48 hours after drug cessation is unusual but the QTc of 526 ms confirms ongoing IKr blockade
• C) The polymorphic VT represents flecainide-induced proarrhythmia; the patient was inadvertently administered oral flecainide by a well-meaning floor nurse who misidentified it as a routine antiarrhythmic pill in the discharge medication reconciliation; the Class Ic mechanism explains the polymorphic VT in this structurally normal heart
• D) The event represents exercise-induced polymorphic VT from unmasked catecholaminergic polymorphic ventricular tachycardia (CPVT) triggered by the emotional stress of the hospitalization; quinidine's alpha-adrenergic blocking properties normally suppress CPVT episodes, and their removal after quinidine cessation has unmasked the underlying condition
• E) This represents atrial flutter with 1:1 conduction misidentified as polymorphic VT on telemetry; without quinidine's sodium channel block slowing the flutter rate, the flutter has returned to its typical rate of 300 beats per minute and is now conducting 1:1 through the previously AV nodal-protected circuit; the twisting morphology reflects rate-dependent bundle branch aberration at 300 beats per minute

20. [CASE 5 — QUESTION 4] The TdP resolves spontaneously and the patient is stabilized on magnesium supplementation. Quinidine is permanently discontinued. The patient's atrial flutter remains a clinical problem and rhythm control is desired. He has no structural heart disease, normal renal function, and no asthma. Digoxin will not be restarted. Which of the following represents the most appropriate rhythm control strategy going forward?

• A) Restart quinidine at half the previous dose (100 mg three times daily) with proactive 50 percent reductions in warfarin and digoxin doses; the TdP event was pause-dependent and can be prevented by prescribing a lower-dose AV nodal blocking agent that avoids sinus pauses; the drug interaction risks were from inadequate dose adjustment, not from the drug itself
• B) Start amiodarone 200 mg daily; given the patient's history of TdP on quinidine, all other antiarrhythmic drugs except amiodarone are contraindicated in this patient because they all carry QT-prolonging risk; amiodarone is the only agent without meaningful QTc effects
• C) Start sotalol 80 mg twice daily as an outpatient; sotalol provides effective flutter rhythm control through IKr blockade and does not interact with warfarin through CYP2C9 or with digoxin through P-glycoprotein; outpatient initiation is appropriate given his normal renal function and the absence of prior QT prolongation on other agents
• D) Start flecainide 100 mg twice daily with a concurrent AV nodal blocking agent (such as metoprolol, increasing his current dose if needed, or switching to diltiazem for rate control in flutter); flecainide is appropriate because this patient has no structural heart disease, no asthma, and normal renal function; it does not interact with warfarin through CYP2C9 or with digoxin through P-glycoprotein (at clinically meaningful levels), and does not prolong the QTc; an AV nodal blocking agent is mandatory to prevent flutter 1:1 conduction
• E) Rate control alone with metoprolol; following a QT-prolonging event (TdP) from any antiarrhythmic agent, pharmacological rhythm control is permanently contraindicated because the electrophysiological substrate that predisposed to TdP will predispose to proarrhythmia from any future antiarrhythmic; catheter ablation is the only acceptable rhythm control approach

21. [CASE 6 — QUESTION 1] Which of the following best characterizes this presentation and explains the correct immediate management?

• A) The ANA titer of 1:320 with negative anti-dsDNA and normal complement is inconsistent with drug-induced lupus; this serological profile is characteristic of idiopathic SLE triggered de novo by procainamide's immunostimulatory properties; the drug should be continued because discontinuation does not affect idiopathic SLE, and hydroxychloroquine should be started
• B) This is procainamide-induced DILS, but the procainamide level of 7.4 mcg/mL is within the therapeutic range, confirming that toxic drug concentrations are not responsible; DILS at therapeutic levels does not require drug discontinuation and can be managed with hydroxychloroquine while continuing procainamide for VT suppression
• C) This is a classic presentation of procainamide-induced drug-induced lupus-like syndrome (DILS): ANA positivity with absent anti-dsDNA antibodies is the key distinguishing feature from idiopathic SLE, where anti-dsDNA is typically present; the articular and serositis manifestations after 16 months of therapy are consistent with DILS; procainamide must be discontinued immediately; the syndrome is generally reversible over weeks to months after drug withdrawal; an alternative VT management strategy must be urgently identified
• D) The serological profile (ANA positive, anti-dsDNA negative) represents NAPA-induced immune complex disease rather than procainamide-induced DILS; NAPA accumulation at the current CrCl of 62 mL/min is responsible for the autoimmune manifestations; reducing the procainamide dose by 50 percent to lower NAPA production will resolve the syndrome while maintaining VT suppression
• E) The clinical and serological findings are consistent with procainamide-induced DILS but the drug cannot be discontinued because no alternative VT management exists; instead, low-dose prednisone 10 mg daily should be started to suppress the autoimmune manifestations while procainamide is continued, with reassessment in three months

22. [CASE 6 — QUESTION 2] Procainamide is discontinued. As part of the evaluation, a new echocardiogram is obtained that reveals an LVEF of 40% with mild inferior wall hypokinesis ; findings not previously documented, likely representing subclinical ischemic cardiomyopathy. Which of the following best describes the impact of this finding on subsequent VT management options?

• A) The newly documented structural heart disease (LVEF 40%, inferior wall hypokinesis suggesting occult ischemic cardiomyopathy) eliminates Class Ic agents (flecainide, propafenone) from consideration for VT management by the CAST principle; amiodarone is the most appropriate pharmacological antiarrhythmic for VT suppression in structural heart disease; ICD implantation should be strongly considered given LVEF of 40% and documented sustained VT ; this patient meets secondary prevention ICD criteria; mexiletine can be considered as an adjunct to amiodarone for refractory VT burden
• B) The LVEF of 40% eliminates all antiarrhythmic options except mexiletine; Class Ic agents are contraindicated by CAST, Class Ia agents are contraindicated in structural disease by an analogous principle, and amiodarone is too toxic for long-term use in a 55-year-old patient; mexiletine as sole Class Ib therapy is the only acceptable pharmacological approach
• C) The structural disease finding eliminates amiodarone from consideration because amiodarone's negative inotropic properties are contraindicated in any patient with LVEF below 45%; flecainide can be used because the inferior wall hypokinesis indicates diastolic dysfunction rather than systolic impairment, and Class Ic agents are safe in diastolic dysfunction with preserved contractility
• D) The LVEF of 40% has no impact on antiarrhythmic options because the CAST contraindication for Class Ic agents applies specifically to post-myocardial infarction patients with documented MI on prior imaging; occult ischemic changes without confirmed prior MI documentation do not invoke the CAST principle, and flecainide remains available
• E) The structural disease finding eliminates all pharmacological VT management options; the only appropriate management is immediate ICD implantation and ablation of the VT circuit; antiarrhythmic drugs in any class are contraindicated when structural disease co-exists with VT because any sodium or potassium channel blockade amplifies the heterogeneous conduction substrate

23. [CASE 6 — QUESTION 3] Six weeks after procainamide discontinuation, the patient's joint symptoms have substantially improved and the malar rash has resolved. His ANA titer remains elevated at 1:160. He asks two questions: (1) when will the ANA normalize completely, and (2) could he take quinidine or disopyramide safely without developing DILS? Which of the following best answers both questions?

• A) The ANA will normalize completely within four weeks of procainamide discontinuation; drug-induced ANA is pharmacologically induced and reverses rapidly once the causative drug is cleared; quinidine and disopyramide carry identical DILS risk to procainamide because all three Class Ia agents share the hydroxylamine metabolic pathway responsible for nuclear protein modification
• B) The ANA will normalize completely within 12 months and the anti-dsDNA will transiently become positive as the DILS resolves ; a pattern called seroreversion that distinguishes true SLE from DILS; quinidine and disopyramide are safe alternatives without DILS risk because they lack the N-oxidation metabolic pathway that produces immunogenic hydroxylamine metabolites
• C) The ANA may never normalize because procainamide DILS produces permanent modification of nuclear protein antigens that sustain ANA production indefinitely; quinidine and disopyramide carry equal DILS risk because all Class Ia agents share the acetylation pathway responsible for the autoimmune response; a different drug class must be used permanently
• D) The ANA will normalize within six weeks because DILS is mediated by drug-protein hapten binding that reverses as the drug is eliminated; quinidine is contraindicated in patients with prior procainamide DILS because they share the same chemical scaffold and cross-reactive immune responses are universal; disopyramide has no DILS risk
• E) The ANA will likely decline gradually over months to a year but may not completely normalize in all patients ; ANA titers can persist for months to years after procainamide discontinuation; anti-dsDNA will remain negative throughout, which distinguishes the resolving DILS from idiopathic SLE; quinidine and disopyramide carry substantially lower DILS risk than procainamide because they do not undergo the N-oxidation to immunogenic hydroxylamine metabolites that is central to procainamide's autoimmune mechanism; however, no Class Ia agent is completely free of autoimmune risk, and close monitoring for DILS features would be appropriate if either agent were used

24. [CASE 6 — QUESTION 4] The patient is started on amiodarone and undergoes ICD implantation. Eight months later he is admitted with VT storm ; three appropriate ICD shocks within six hours, each terminating sustained VT. He is in sinus rhythm between episodes. Blood pressure is 108/68 mmHg. A trainee physician suggests starting intravenous flecainide to suppress the VT storm. Which of the following is the correct response to this suggestion?

• A) The suggestion is appropriate; while oral flecainide is contraindicated in structural heart disease by the CAST principle, intravenous flecainide bypasses the first-pass metabolism that produces the toxic metabolites responsible for CAST proarrhythmia; IV flecainide is specifically indicated for VT storm in structural heart disease when amiodarone is already maximized
• B) The suggestion is incorrect and must be declined; intravenous flecainide is absolutely contraindicated in this patient with structural heart disease from ischemic cardiomyopathy regardless of the clinical urgency ; the CAST contraindication applies to both oral and intravenous Class Ic administration, and the route of administration does not alter the proarrhythmic mechanism; appropriate management of VT storm in structural heart disease includes intravenous amiodarone supplementation, intravenous beta-blockade to reduce sympathetic triggering, deep sedation, and urgent catheter ablation consultation
• C) The suggestion is appropriate in a VT storm emergency; the CAST contraindication specifies that Class Ic agents should not be initiated in stable outpatients with structural heart disease for chronic rhythm control, but this exception clause is waived in life-threatening VT storm where the immediate mortality risk exceeds the pharmacological proarrhythmic risk; flecainide IV at 2 mg/kg is the correct choice
• D) The suggestion is partially appropriate; intravenous flecainide can be used for VT storm in structural heart disease if the QRS duration is continuously monitored and the infusion is stopped if the QRS exceeds 25 percent above the pre-drug baseline; this safety threshold allows the drug's sodium channel-stabilizing effect while avoiding the degree of conduction slowing that would create new re-entrant circuits
• E) The suggestion is appropriate but the wrong Class Ic agent is being recommended; propafenone IV is preferred over flecainide IV in VT storm in structural heart disease because propafenone's additional beta-blocking properties provide simultaneous sympatholytic activity that reduces the catecholamine excess driving the VT storm; flecainide lacks this beta-blocking property